Altenmüller, E, Jabusch, H-C (2010) Focal dystonia in musicians: phenomenology, pathophysiology, triggering factors, and treatment. Med Probl Perform Art 25:3–9.
Argyelan, M, Carbon, M, Niethammer, M, Ulug, AM, Voss, HU, Bressman, SB, Dhawan, V, Eidelberg, D (2009) Cerebellothalamocortical connectivity regulates penetrance in dystonia. J Neurosci 29:9740–9747.
Berardelli, A (1998) The pathophysiology of primary dystonia. Brain 121:1195–1212.
Borgelt, LM, Franson, KL, Nussbaum, AM, Wang, GS (2013). The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33:195–209.
Breakefield, XO, Blood, AJ, Li, Y, Hallett, M, Hanson, PI, Standaert, DG (2008) The pathophysiological basis of dystonias. Nat Rev Neurosci 9:222–234.
Chatterjee, A, Almahrezi, A, Ware, M, Fitzcharles, MA (2002) A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. J Pain Symptom Manage 24:4–6.
Compton, DR, Aceto, MD, Lowe, J, Martin, BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586–594.
Consroe, P, Sandyk, R, Snider, SR (1986). Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277–282.
Fox, SH, Kellett, M, Moore, AP, Crossman, AR, Brotchie, JM (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145–149.
Gauter, B, Rukwied, R, Konrad, C (2004) Cannabinoid agonists in the treatment of blepharospasm: a case report study. Neuro Endocrinol Lett 25:45–48.
Haberstick, BC, Young, SE, Zeiger, JS, Lessem, JM, Hewitt, JK, Hopfer, CJ (2014) Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend 136:158–161.
Hallett, M (2006) Pathophysiology of writer’s cramp. Hum Mov Sci 25:454–463.
Hallett, M (2011) Neurophysiology of dystonia: the role of inhibition. Neurobiol Dis 42:177–184.
Herkenham, M, Lynn, AB, Johnson, MR, Melvin, LS, de Costa, BR, Rice, KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563–583.
Iversen, L (2003) Cannabis and the brain. Brain J Neurol 126:1252–1270.
Jabusch, H-C, Schneider, U, Altenmüller, E (2004) Delta9-tetrahydrocannabinol improves motor control in a patient with musician’s dystonia. Mov Disord 19:990–991.
Kluger, B, Triolo, P, Jones, W, Jankovic, J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30:313–327.
Koppel, BS, Brust, JC, Fife, T, Bronstein, J, Youssof, S, Gronseth, G, Gloss, D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders – report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82:1556–1563.
Kreitzer, AC, Regehr, WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717–727.
Lile, JA, Kelly, TH, Charnigo, RJ, Stinchcomb, AL, Hays, LR (2013) Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Delta(9)-THC in cannabis users. J Clin Pharmacol 53:680–690.
Llano, I, Leresche, N, Marty, A (1991) Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 6:565–574.
Martinasek, MP, McGrogan, JB, Maysonet, A (2016) A systematic review of the respiratory effects of inhalational marijuana. Respir Care 61:1543–1551.
Matsuda, LA, Bonner, TI, Lolait, SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535–550.
Moreira, FA, Grieb, M, Lutz, B (2009) Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23:133–144.
Müller-Vahl, KR, Prevedel, H, Theloe, K, Kolbe, H, Emrich, HM, Schneider, U (2003) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacol 28:384–388.
Neychev, VK, Fan, X, Mitev, VI, Hess, EJ, Jinnah, HA (2008) The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain 131:2499–2509.
Pitler, TA, Alger, BE (1992) Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci 12:4122–4132.
Richter, A, Löscher, W (1994) (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 264:371–377.
Richter, A, Löscher, W (2002) Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. Eur J Pharmacol 454:145–151.
Richter, L, Pugh, BS, Ball, SA (2016) Assessing the risk of marijuana use disorder among adolescents and adults who use marijuana. Am J Drug Alcohol Abuse 13:1–14.
Riedel, G, Davies, SN (2005) Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 168:445–477.
Russo, E, Guy, GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66:234–246.
Sañudo-Peña, MC, Patrick, SL, Khen, S, Patrick, RL, Tsou, K, Walker, JM (1998) Cannabinoid effects in basal ganglia in a rat model of Parkinson’s disease. Neurosci Lett 248:171–174.
Secades-Villa, R, Garcia-Rodriguez, O, Jin, CJ, Wang, S, Blanco, C (2014) Probability and predictors of the cannabis gateway effect: a national study. Int J Drug Policy 26:135–142.
Trigo, JM, Lagzdins, D, Rehm, J, Selby, P, Gamaleddin, I, Fischer, B, Barnes, AJ, Huestis, MA, Le Foll, B (2016) Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend 161:298–306.
Uribe Roca, MC, Micheli, F, Viotti, R (2005) Cannabis sativa and dystonia secondary to Wilson’s disease. Mov Disord 20:113–115.
Volkow, ND, Baler, RD, Compton, WM, Weiss, SR (2014a) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227.
Volkow, ND, Wang, GJ, Telang, F, Fowler, JS, Alexoff, D, Logan, J, Jayne, M, Wong, C, Tomasi, D (2014b) Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci 111:3149–3156.
Warner, LA, Kessler, RC, Hughes, M, Anthony, JC, Nelson, CB (1995) Prevalence and correlates of drug use and dependence in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 52:219–229.
Zadikoff, C, Wadia, PM, Miyasaki, JM, Chen, R, Lang, AE, So, J, Fox, SH (2011) Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial. Basal Ganglia 1:91–95.